explore -WSS

explore

author：knowledge 2025-09-29 22:49:47 - browse：48

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Celiac disease study examines precisely how gluten triggers injury

hotspot

WSS

Georgia court denies Trump's request to quash DA's 2020 election probe

Europe sees delivery challenges ahead on Alzheimer's therapies

Georgia court denies Trump's request to quash DA's 2020 election probe

Woman gored by Bison at Yellowstone

Medicare Advantage beneficiaries sue Humana over algorithm use

Mike Pence clashes with Tucker Carlson in Iowa

entertainment

explore

leisure time

Psychedelics group wrestles with new pharma identity

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Drug repurposing or repositioning? The language matters

Hospitals owned by private equity see complications spike 25%

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Novavax promises a turnaround & Lilly roils the obesity market

Celiac disease study examines precisely how gluten triggers injury

Hollywood unions extend contract negotiations for actors

Argenx drug significantly slows progression of nerve disorder

explore

Why police arrested suspected Gilgo Beach killer away from his house

Why police arrested suspected Gilgo Beach killer away from his house

Mike Pence clashes with Tucker Carlson in Iowa

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

What STAT readers think about the FDA and patient advocacy

explore

hotspot

entertainment

focus